Evidence map›Paper›PMID 30269265›Full record

ArticleEndocrine2019

Prevalence and reproductive manifestations of macroprolactinemia.

Amanpreet Kaur Kalsi, Ashutosh Halder, Manish Jain, P K Chaturvedi, J B Sharma

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Hyperprolactinaemia.Journal of clinical medicine · 2019
    Review
  10. PCOS and Hyperprolactinemia: what do we know in 2019?Clinical medicine insights. Reproductive health · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Amanpreet Kaur KalsiDepartment of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, India. kalsi.amanpreetkaur@gmail.com.
Ashutosh HalderDepartment of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, India. ashutoshhalder@gmail.com.
Manish JainDepartment of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, India.
P K ChaturvediDepartment of Reproductive Biology, All India Institute of Medical Sciences, New Delhi, India.
J B SharmaDepartment of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMacroprolactinemia is characterized by predominance of macroprolactin molecules in circulation and generally has extra-pituitary origin. Macroprolactin is viewed as biologically inactive, therefore asymptomatic, and thus may not require any treatment or prolonged follow-up. In addition, data on prevalence of macroprolactinemia and its clinical manifestation are also rare. Therefore, the present study was aimed to find out prevalence of macroprolactinemia and its association, if any, with reproductive manifestations. MATERIAL AND

methodsMacroprolactin was measured in 102 hyperprolactinemia cases (>100 ng/ml prolactin level), 135 physiological hyperprolactinemia cases (50 pregnant and 85 lactating females; >100 ng/ml prolactin level) and 24 controls. Poly ethylene glycol (PEG) precipitation method was carried out to screen macroprolactin. Prolactin recovery of <25% was considered overt macroprolactinemia. Detailed clinical data was recorded which included complete medical history, physical examination and hormone measurements besides CT/MRI for pituitary abnormalities.

resultsPrevalence of macroprolactinemia was 21.57% (22/102) in hyperprolactinemia (prolactin >100 ng/ml). There was no case of macroprolactinemia in physiological hyperprolactinemia, or healthy control females. Reproductive manifestations were present in 72.73% (16/22) macroprolactinemia cases, out of which macroprolactinemia was the sole cause of associated reproductive manifestations in 68.7% (11/16) cases. Reversal of reproductive dysfunction/s was observed in five cases with appropriate treatment for high macroprolactin.

conclusionMacroprolactinemia prevalence was found to be 21.5%, out of which 72.73% cases had associated reproductive dysfunctions.

Indexed as

Abortion, SpontaneousAdultCase-Control StudiesErectile DysfunctionFemaleHumansHyperprolactinemiaInfertilityLibidoMaleMenstruation DisturbancesMiddle AgedPituitary NeoplasmsPregnancyPrevalenceProlactinProlactinprolactin, polymericHyperprolactinemiaMacroprolactinMacroprolactinemiaPolyethylene Glycol PrecipitationProlactin

Identifiers

PMID30269265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.